There is some additional independent evidence implicating SFRP2 as an up-regulated extracellular signaling component that increases in aging tissues [31], while a recent study showed that targeting SFRP2 can alleviate aging-dependent resistance to bevacizumab when treating patients against angiogenesis in melanoma [32, 33]. This evidence concerns the gene SFRP2 and melanoma.